11 results about "Oncostatin M" patented technology

The invention discloses application of a neutralizing antibody of oncostatin M in preparation of a medicine for treating bronchial pulmonary dysplasia. The application proves that the intrauterine inflammation can cause BPD-like lung lesion to the filial generation mouse, and the OSM expression level in the mouse lung tissue one day after the intrauterine inflammation filial generation is grown is obviously higher than that of a control group; the OSM level of the BPD group is higher than that of the non-BPD group in the umbilical blood sample of the premature infant; in-vitro experiments show that the OSM treatment can cause lung epithelial cell injury; by dripping a recombined OSM neutralizing antibody into the nose of a newborn mouse, down-regulation of the OSM level in the lung of the mouse is realized, filial generation lung injury induced by the intrauterine inflammation can be repaired, and the OSM can be used as a treatment target of the BPD caused by the intrauterine inflammation.

The present disclosure relates to methods, uses, and compositions (e.g., articles of manufacture and kits) comprising anti-OSMR [beta] antibodies, such as wealizumab, for the treatment of inflammatory gastrointestinal diseases (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC (e.g., moderate to severe UC)) and Crohn's disease (CD)) associated with the oncostatin M (OSM) pathway.

The invention relates to a liver cancer organoid culture medium and application thereof, and belongs to the technical field of medicines. The liver cancer organ-like culture medium disclosed by the invention is prepared from the following components: AdvDMEM F12, HEPES, GlutaMAX, B27, EGF (Epidermal Growth Factor), N-acetyl-L-cysteine, gastrin, HGF (Hepatocyte Growth Factor), FGF-10 (Fibroblast Growth Factor), A83-01, nicotinamide, N2, an adenylate cyclase activator, a three-antibody antibiotic, R-spondin1, Wnt-3a, Y-2763, Noggin, oncostatin M and FGF-23. The culture medium is rich in nutrition and reasonable in component; the liver cancer organoid cell spheres cultured by using the culture medium can stably grow for a long time, continuously amplify and repeatedly cryopreserve. When the culture medium is used for preparing the liver cancer organ model, a foundation is laid for knowing the pathogenesis of liver cancer and screening drugs.

This invention relates to the field of biomedical technology, and in particular to mesenchymal stem cells, their preparation methods, and applications. The method for preparing mesenchymal stem cells includes the following steps: culturing the mesenchymal stem cells under hypoxic conditions with an oxygen volume fraction of 2%–4%, and during the hypoxic culture, pre-activating the mesenchymal stem cells by contacting them with an induction system containing 1–3 ng / mL Oncostatin M, 1–10 ng / mL IL-1β, and 2–10 ng / mL HMGB1 for 6–24 hours. Mesenchymal stem cells treated by this method can significantly inhibit lymphocyte proliferation, reduce the proportion of pro-inflammatory T cell subsets such as Th1 and Th17, increase the proportion of Treg cells, and effectively reduce the level of the inflammatory factor TNF-α.

A chimeric antigen receptor (CAR) comprises an extracellular antigen-binding domain, which comprises a polypeptide that binds to oncostatin M receptor (OSMR), leukemia inhibitory factor receptor (LIFR), a heterodimer between transmembrane glycoprotein 130 (gp130) receptor and OSMR, and / or a heterodimer between gp130 receptor and LIFR.

The invention discloses application of a pegylated interferon and proto-oncogene product targeted inhibitor in synergistic treatment of kidney cancer. Specifically, the invention provides an application of an active ingredient combination, the active ingredient combination comprises a PEG interferon and a proto-oncogene product targeting inhibitor, and the combination is used for preparing a medicine composition for co-treating kidney cancer. The active component composition can effectively and synergistically inhibit kidney cancer, and can remarkably reduce toxic and side effects, so that the composition can be widely applied to targeted treatment of tumors.

The invention discloses application of oncostatin M as a biomarker in preparation of a kit for diagnosing pseudomonas aeruginosa infectious pneumonia, and belongs to the technical field of biology. The cytokine oncostatin M is adopted as a biomarker for detecting the lung pseudomonas aeruginosa, and compared with CRP commonly used in clinic, the oncostatin M has high sensitivity, can be used as a specific inflammatory factor, indirectly reflects the infection state of the lung pseudomonas aeruginosa, preliminarily prompts the load of the pseudomonas aeruginosa, and can be used for detecting the lung pseudomonas aeruginosa. The auxiliary diagnosis of the pseudomonas aeruginosa infectious pneumonia is realized.

The present invention discloses a pulmonary vascular endothelial barrier damage model, a construction method and an application thereof, and relates to the field of biotechnology. The construction method of the pulmonary vascular endothelial barrier damage model comprises the following steps: after adaptive feeding healthy mice for one week, anesthetizing them with drugs, pre-treating oncostatin M recombinant protein and instilling it into the mouse lungs through the airway to obtain a pulmonary vascular endothelial barrier damage model; the present invention also discloses a pulmonary vascular endothelial barrier damage model and an application of the model in preparing a pulmonary vascular disease research model and an application of the model in preparing drugs for treating pulmonary vascular diseases; the pulmonary vascular endothelial barrier damage model provided by the present invention, a construction method and an application thereof, oncostatin M protein binds to type II oncostatin M receptors on endothelial cells, activates downstream signaling pathways, and causes endothelial barrier damage, thereby providing a clear target for endothelial barrier damage and facilitating in-depth exploration of the mechanism of lung injury.

The invention relates to a bile duct cancer organoid culture medium and application thereof, and belongs to the technical field of biomedicine. The bile duct cancer organ culture medium provided by the invention is prepared from the following components: a TGF (Transforming Growth Factor)-beta signal channel inhibitor A83-01, an epidermal growth factor (EGF), a fibroblast growth factor FGF10, a hepatocyte growth factor HGF, an adenylate cyclase activator Forskolin, a gastrin analogue Gastrin I, nicotinamide Nicotinamide, a ROCK kinase inhibitor Y-27632, glucocorticoid dexamethasone, a compound antibiotic, a cell factor oncostatin M and FGF-23. The culture medium disclosed by the invention is reasonable in formula design, all the components have a synergistic effect, long-term stable amplification of bile duct cancer organs can be effectively maintained, and a good cryopreservation resuscitation characteristic is maintained. A liver cancer organ model established on the basis of the culture medium provides a reliable experimental platform for exploring pathogenesis of bile duct cancer and developing related drug research and development.

The present invention provides a culture medium for culturing primary gastric cancer cells, comprising an MST1 / 2 kinase inhibitor, a ROCK kinase inhibitor, at least one of a B27 additive and an N2 additive, basic fibroblast growth factor, CHIR99021, epidermal growth factor, an ITS cell culture additive, SB202190, dexamethasone, N-acetyl-L-cysteine, gastrin, A8301, oncostatin M, and cholera toxin. The present invention also relates to a culture method using the primary cell culture medium. The culture method uses the culture medium to culture primary gastric cancer cells on a culture vessel coated with extracellular matrix glue, thereby rapidly proliferating the primary cells.

The application discloses application of a compound specifically targeting onimstatin M in preparation of a medicine for resisting Pseudomonas aeruginosa infectious lung injury, relates to the technical field of biological medicine, and the compound plays a role in resisting Pseudomonas aeruginosa infectious lung injury through specific binding of onimstatin M protein; the compound can be specifically and stably combined at a key function site of the onimstatin M protein; the compound is used for reducing the content of TNF-alpha, IL6 and IL1beta in serum of an individual with lung injury caused by Pseudomonas aeruginosa infection; a medicine composition is provided, and the medicine composition comprises an effective amount of the compound and a pharmaceutically acceptable carrier; based on the new target of onimstatin M, an active medicine capable of effectively reducing lung injury is developed, and in particular, a compound overcoming the limitations of high cost and injection administration of an antibody medicine.